亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Omalizumab for severe atopic dermatitis in 4- to 19-year-olds: the ADAPT RCT

奥马佐单抗 斯科拉德 医学 安慰剂 特应性皮炎 随机对照试验 生活质量(医疗保健) 置信区间 皮肤科生活质量指数 免疫球蛋白E 安慰剂对照研究 物理疗法 心理干预 内科学 儿科 双盲 皮肤病科 免疫学 抗体 替代医学 护理部 疾病 病理 精神科
作者
Susan Chan,Suzie Cro,Victoria R. Cornelius,Rahi Jahan,Suzana Radulović,Gideon Lack
出处
期刊:Efficacy and mechanism evaluation [NIHR Journals Library]
卷期号:9 (5): 1-110 被引量:6
标识
DOI:10.3310/wcxn5739
摘要

Background Evidence for systemic treatments for severe childhood eczema is limited. Systemic immunosuppressants are unlicensed for use in children and are associated with unwanted side effects. Objective To examine the role of anti-immunoglobulin E (IgE) [omalizumab (Xolair®, Novartis Pharmaceuticals UK Ltd, Frimley, UK)] in children and young people with severe eczema. Design A double-blind, placebo-controlled, parallel-arm randomised (1 : 1) trial. Setting A single specialist centre – Guy’s and St Thomas’ NHS Foundation Trust, London. Participants Atopic children and young people (aged 4–19 years) with severe eczema. Interventions Treatment with omalizumab or placebo for 24 weeks. Main outcome measures The primary outcome was eczema severity, measured using the objective SCORing Atopic Dermatitis (SCORAD) at 24 weeks. Secondary outcomes included validated measures of eczema severity, quality of life (QoL) and potent topical steroid use. Results Sixty-two participants, with a median baseline total IgE level of 8373 kU/l, received treatment with omalizumab (n = 30) or placebo (n = 32). The unadjusted mean objective SCORAD score at week 24 was 43.1 [standard deviation (SD) 12.5] for participants in the omalizumab arm and 49.2 (SD 11.3) for participants in the placebo arm. After adjustment for baseline objective SCORAD score, age and IgE level, the mean difference between arms at 24 weeks was –6.9 [95% confidence interval (CI) –12.2 to –1.5;p = 0.013], in favour of omalizumab. The mean objective SCORAD scores improved by –12.4 and –5.1 in the omalizumab and placebo arms, respectively, by 24 weeks. Secondary outcome measure estimates were also in favour of omalizumab for eczema severity at 24 weeks: the adjusted mean treatment arm difference was –8.3 (95% CI –15.1 to –1.1;p = 0.024) for total combined objective and subjective SCORAD and –6.7 (95% CI –13.2 to –0.1;p = 0.046) for the Eczema Area and Severity Index, with less effect on the Patient-Oriented Eczema Measure (POEM; –1.1, 95% CI –4.6 to 2.4;p = 0.527). Treatment estimate precision was limited by the sample size. The QoL measures favoured omalizumab, with an improvement (reduction) in both (Children’s) Dermatology Life Quality Index [(C)DLQI] score (mean –3.5, 95% CI –6.4 to –0.5;p = 0.022) and Paediatric Allergic Disease Quality of Life Questionnaire score (mean –0.5, 95% CI –0.9 to 0.0;p = 0.050). The mean (C)DLQI score improved by 50%, from 17.0 (SD 5.6) at baseline to 8.5 (SD 5.9) at week 24, for patients treated with omalizumab. Improvements were seen despite lower potent topical steroid use in the omalizumab arm, with 48% more days of use than (109 days in the placebo arm vs. 161 days in the omalizumab arm) and twice the body surface area coverage of (15.5% in the placebo arm vs. 31.3% in the omalizumab arm) the placebo arm. There were fewer treatment failures and new systemic immunosuppression initiations in the omalizumab arm. There was no difference in the numbers of cases of infective eczema and eczema exacerbation. There was one suspected severe adverse reaction in the omalizumab arm. In each arm, six participants reported a total of seven severe adverse events that were unrelated to treatment. Non-serious respiratory and dermatological adverse event rates were higher in the placebo arm (incidence rate ratio 0.69, 95% CI 0.49 to 0.96). Conclusions Omalizumab, in a highly atopic paediatric population with severe eczema, reduced eczema severity and improved QoL despite a reduction in potent steroid use and highly elevated total IgE levels. Omalizumab, with its favourable side effect profile, warrants further study as a treatment option for this difficult-to-manage population. Further studies are needed to clarify the role of omalizumab. Treatment benefit became more apparent towards 24 weeks and persisted after treatment stopped. The optimal duration of treatment needs to be determined. Trial registration This trial is registered as ISRCTN15090567, EudraCT 2010-020841-29 and ClinicalTrials.gov NCT02300701. Funding This project was funded by the Efficacy and Mechanism Evaluation programme, a Medical Research Council and National Institute for Health and Care Research (NIHR) partnership. This will be published in full inEfficacy and Mechanism Evaluation; Vol. 9, No. 5. See the NIHR Journals Library website for further project information. A grant from the Guy’s and St Thomas’ Charity supported the Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT). Omalizumab and the placebo were supplied by Novartis Pharmaceuticals UK Ltd.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
过客完成签到,获得积分10
2秒前
3秒前
Lee发布了新的文献求助10
3秒前
十三完成签到 ,获得积分10
5秒前
KaK完成签到,获得积分10
8秒前
14秒前
大意的山水完成签到,获得积分10
15秒前
迷路万天完成签到,获得积分10
16秒前
17秒前
绿鬼蓝完成签到 ,获得积分10
17秒前
域尔完成签到,获得积分10
17秒前
18秒前
20秒前
21秒前
清平道人完成签到,获得积分0
23秒前
maoxiaodi发布了新的文献求助10
25秒前
白华苍松发布了新的文献求助10
27秒前
喵喵张完成签到 ,获得积分10
27秒前
111完成签到 ,获得积分10
29秒前
田様的应助被听话的含羞草采纳,获得10
30秒前
轨迹。完成签到 ,获得积分10
31秒前
在水一方的应助被美满惜雪采纳,获得10
36秒前
顾矜的应助被谌坚采纳,获得10
38秒前
38秒前
橱窗完成签到,获得积分10
39秒前
39秒前
LL完成签到 ,获得积分10
40秒前
fan完成签到 ,获得积分10
41秒前
41秒前
hfhkjh完成签到,获得积分10
42秒前
俏皮的绮波完成签到,获得积分10
42秒前
42秒前
cfyoung发布了新的文献求助10
43秒前
cfyoung发布了新的文献求助10
43秒前
44秒前
44秒前
友好胜完成签到 ,获得积分0
44秒前
帅气忻完成签到 ,获得积分10
44秒前
45秒前
45秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184964
求助须知:如何正确求助?哪些是违规求助? 9573917
关于积分的说明 21833687
捐赠科研通 7782425
什么是DOI,文献DOI怎么找? 3434429
关于科研通互助平台的介绍 2558672
邀请新用户注册赠送积分活动 2481161